Is Alzheimer’s Treatment Moving Beyond the Amyloid Shadow? Pepinemab to Use Biomarker Data to Seek Its Next Clinical Trial

Alzheimer’s drug development is undergoing a subtle shift: anti-amyloid therapies have finally achieved some clinical results, but their efficacy, risks, and applicable patient populations remain limited. That has led researchers to ask again which other biological pathways in the disease process might be amenable to intervention. Vaccinex is scheduled to present new biomarker data for pepinemab in Alzheimer’s disease and discuss its late-stage Phase 2 clinical trial plan on July 13, 2026, at the Alzheimer’s Association International Conference (AAIC) in London.

According to information released by the company, the presentation will take place in a Featured Research Session focused on “therapeutic mechanisms beyond amyloid.” Pepinemab is a monoclonal antibody targeting SEMA4D. Vaccinex positions it as a first-in-class therapy, attempting to intervene through neuroinflammation, glial cell activation, and synaptic protection rather than directly clearing amyloid plaques in the brain.

This strategy matters because Alzheimer’s disease is not a single-pathway disease. Amyloid and tau proteins remain core pathologies, but immune-cell responses, vascular and synaptic function, and neural network degeneration may also jointly drive cognitive decline. If pepinemab’s biomarker data can support its mechanistic hypothesis, what it offers would not be another competitor of the same kind, but a route that could potentially complement existing therapies.

However, the currently public information remains quite limited. The pre-conference announcement only states that new biomarker data and a late-stage Phase 2 trial plan will be reported; it has not yet provided complete data, patient numbers, statistical results, changes in clinical scales, or which biomarkers showed consistent associations with cognitive function. Therefore, the more cautious reading is that this is an occasion for the upcoming disclosure of clinical translational clues, not a milestone at which efficacy has already been proven.

The design of the late-stage Phase 2 trial will be the key point for interpretation. For neurodegenerative diseases, early signals are often affected by patient heterogeneity, disease duration, comorbidities, and endpoint sensitivity. If the study population is too broad, potential effects may be diluted; if the endpoint selection is not precise, biomarker changes may not necessarily translate into improvements patients can feel. Vaccinex needs to clearly explain how it plans to select participants, track disease changes, and connect mechanistic evidence to clinical outcomes.

Background Context

Pepinemab has also previously been discussed within the non-amyloid pathways in the Alzheimer’s treatment landscape. Therapies of this kind face both opportunity and pressure: on one hand, existing anti-amyloid drugs leave unmet medical needs; on the other hand, any new mechanism must cross a higher evidence threshold and prove that it does not merely make biomarkers look better, but can change the disease course or bring clear benefits to specific patients.

For that reason, what may be most worth reading in the July 13 presentation is not a single number, but whether the overall clinical logic is mature. If the new data can identify a clear biological response, a reasonable approach to patient stratification, and an executable late-stage Phase 2 endpoint design, pepinemab may have a chance to move “beyond amyloid” from an R&D slogan into a therapeutic hypothesis that can be tested in clinical trials.